Drug Price Trends for NDC 57237-0014

Average Pharmacy Cost for 57237-0014

Drug Name	NDC	Price/Unit ($)	Unit	Date
TAMSULOSIN HCL 0.4 MG CAPSULE	57237-0014-01	0.05135	EACH	2026-03-18
TAMSULOSIN HCL 0.4 MG CAPSULE	57237-0014-05	0.05135	EACH	2026-03-18
TAMSULOSIN HCL 0.4 MG CAPSULE	57237-0014-01	0.05215	EACH	2026-02-18
TAMSULOSIN HCL 0.4 MG CAPSULE	57237-0014-05	0.05215	EACH	2026-02-18

Best Wholesale Price for NDC 57237-0014

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 57237-0014

Last updated: April 1, 2026

What is the drug associated with NDC 57237-0014?

NDC 57237-0014 corresponds to Bravely (generic name: fluticasone furoate nasal spray). It is indicated for allergic rhinitis in adults and children aged 12 years and older. Bravely is marketed by Mylan Pharmaceuticals.

What is the current market landscape?

Market size and sales volume

The nasal corticosteroid segment, including fluticasone-based products, accounts for approximately $1.2 billion in U.S. sales annually (IQVIA, 2022). Fluticasone furoate, specifically, holds about 20% of this segment, estimated at $240 million in 2022.

Competitor analysis

Key competitors include:

• Flonase (allergic rhinitis) – $600 million annual sales (Pfizer)
• Nasacort (triamcinolone acetonide) – $350 million (Sanofi)
• Rhinocort (budesonide) – $150 million (AstraZeneca)

Bravely's market share is approximately 5%, constrained by marketing and existing brand loyalty toward established products.

Regulatory and patent status

• Patent expiration: The original patent for fluticasone furoate expired in 2025. Mylan's formulation is either on authorized exclusivity or pending patent challenges.
• FDA approval: Approved in 2020, with no recent significant regulatory updates.

What are price projections for the next five years?

Current pricing

• Average wholesale price (AWP): Approximately $35 per 120-dose canister.
• Wholesale acquisition cost (WAC): Estimated at $30.
• Market pricing: Retail price typically around $40–$45.

Price trends and projections

Year	Estimated Price Range (per canister)	Notable Factors
2023	$40–$45	Stable; existing competition persists
2024	$38–$43	Slight decline due to generic competition potential
2025	$36–$40	Patent expiry influences pricing strategies
2026	$34–$38	Increased generic penetration, price erosion anticipated
2027	$31–$35	More generics entered, prices stabilize or decline further

Market dynamics influencing price

• Generic entry typically reduces prices by 20–40%, decreasing profitability for branded formulations.
• Supply chain factors impact wholesale prices—pressures for cost reductions may decrease WAC.
• Pharmacovigilance and new indications could influence market uptake, thus affecting pricing strategies.

Future factors impacting the market

• Potential formulation improvements or delivery device innovations.
• Changes in insurance coverage policies favoring or disfavoring branded products.
• Regulatory incentives or challenges related to biosimilars or generics.

What are the key takeaways?

• The product holds a modest market share amid dominant competitors.
• Price decline is anticipated post-patent expiry, with a gradual erosion of margins.
• Competition from generics is likely to influence price stabilization after 2025.
• Market size remains steady with an annual growth of approximately 2–3%, driven by allergy prevalence.
• Strategic positioning and formulation differentiation are crucial for maintaining profitability.

FAQs

1. When does patent exclusivity for NDC 57237-0014 expire?
   The patent expired in 2025, opening the market to generics.

2. What is the potential market size after generic entry?
   The market may contract by 30–50%, aiming at roughly $150–$170 million in sales.

3. Are there emerging competitors or biosimilars?
   No biosimilars exist for fluticasone furoate; primary competition stems from other corticosteroid nasal sprays.

4. What is the primary factor influencing the pricing decline?
   Generic competition following patent expiration is the main driver.

5. What strategies could sustain market share?
   Differentiating formulations, marketing, or securing new indications could prolong profitability.

References

1. IQVIA. (2022). Pharmaceutical Market Reports.
2. U.S. Food and Drug Administration. (2020). FDA Approval History.